Chinese General Practice ›› 2022, Vol. 25 ›› Issue (25): 3075-3082.DOI: 10.12114/j.issn.1007-9572.2022.0515
Special Issue: 神经退行性病变最新文章合集; 阿尔茨海默病最新文章合集; 述评栏目最新文章合集
• Editorial • Next Articles
Received:
2022-07-14
Revised:
2022-07-18
Published:
2022-09-05
Online:
2022-07-21
Contact:
Wannian LIANG
About author:
通讯作者:
梁万年
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0515
行动领域 | 英国 | 英国北爱尔兰地区 | 澳大利亚 | 卢森堡 | 以色列 | 芬兰 | 爱尔兰 | 希腊 | 意大利 | 美国 | 挪威 | 马耳他 | 韩国 | 印度尼西亚 | 古巴 | 奥地利 | 斯洛文尼亚 | 瑞士 | 英国苏格兰地区 | WHO | 加拿大 | 威尔士 | 丹麦 | 卡塔尔 | 捷克 | 荷兰 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
预防 | 失智症友好意识 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | - | √ | - | √ | √ | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ |
减少危险因素,推迟失智症的发生 | - | √ | - | √ | - | - | - | √ | √ | √ | √ | - | √ | √ | - | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
发布失智症国家(地区)框架和标准策略 | √ | √ | - | - | √ | - | - | - | - | - | - | √ | - | - | - | √ | - | √ | √ | - | - | - | - | √ | √ | √ | |
失智症作为公共卫生优先事项 | - | - | - | √ | √ | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | √ | √ | - | - | √ | - | - | |
识别和描述早期认知障碍 | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | √ | - | - | - | - | - | - | - | - | - | - | - | |
基于社区的预防和管理 | - | - | - | - | - | - | - | - | - | - | √ | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | - | |
促进大脑健康 | - | - | - | - | - | √ | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | |
干预 | 失智症诊断、治疗、照护及干预 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | - | - | √ | √ | √ | √ | √ | √ | - | √ | - | - |
减少不适当的抗精神病药物处方 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | √ | - | - | - | - | - | - | - | |
失智症患者的注册、分类管理 | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
对有失踪风险的患者做出快速响应 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | |
研究 | 建设失智症信息系统 | - | - | - | √ | - | - | √ | √ | √ | √ | - | - | - | √ | - | √ | √ | √ | √ | √ | - | - | - | √ | - | √ |
失智症研究、教育和创新 | - | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
患者在社会建筑环境中生活得更好 | √ | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | √ | - | √ | - | - | √ | - | - | √ | - | |
开发卫生和社会福利技术 | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
技术的可获得性 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | |
支持 | 对失智症照料者的支持 | - | √ | - | √ | √ | √ | √ | √ | √ | √ | - | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
扩大不同护理服务主体的协调与合作 | - | - | - | - | - | - | - | - | √ | - | √ | - | - | √ | - | √ | - | - | √ | - | - | - | √ | √ | √ | √ | |
提高照护人员专业发展 | - | - | - | - | - | - | - | - | √ | - | - | √ | - | √ | √ | - | - | - | - | - | - | - | - | - | - | √ | |
确保患者和护理人员的参与性和自主性 | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | √ | - | - | √ | - | - | - | - | - | - | - | |
实施 | 建立战略领导管理小组 | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | √ |
保障行动计划实施所需资源 | - | √ | - | - | - | - | - | - | - | √ | - | √ | - | √ | - | - | - | - | √ | - | - | √ | √ | √ | |||
优化利益相关者的作用 | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | √ | - | - | - | - | - | - | - | |
立法 | 护理人员的道德和赋权 | - | - | - | √ | - | - | - | - | √ | - | - | √ | - | - | - | - | √ | - | √ | - | - | - | - | - | - | - |
保护失智症患者的权益 | - | √ | - | √ | - | - | - | √ | - | - | - | - | - | √ | √ | - | - | - | √ | - | - | - | - | √ | √ | - | |
评估 | 持续护理、临终支持的质量 | - | √ | √ | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | √ | - | √ | √ | √ | √ | - | √ |
服务的经济可持续性 | - | - | - | - | - | - | - | - | - | - | √ | - | √ | - | - | - | - | √ | - | - | - | - | √ | - | √ | - | |
结果完成情况、时间进度 | - | - | - | - | - | - | - | - | √ | √ | - | - | - | √ | - | - | - | - | - | - | - | - | - | √ | - | √ |
Table 1 Priorities in the action plans on dementia from the WHO and 25 countries/regions
行动领域 | 英国 | 英国北爱尔兰地区 | 澳大利亚 | 卢森堡 | 以色列 | 芬兰 | 爱尔兰 | 希腊 | 意大利 | 美国 | 挪威 | 马耳他 | 韩国 | 印度尼西亚 | 古巴 | 奥地利 | 斯洛文尼亚 | 瑞士 | 英国苏格兰地区 | WHO | 加拿大 | 威尔士 | 丹麦 | 卡塔尔 | 捷克 | 荷兰 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
预防 | 失智症友好意识 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | - | √ | - | √ | √ | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ |
减少危险因素,推迟失智症的发生 | - | √ | - | √ | - | - | - | √ | √ | √ | √ | - | √ | √ | - | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
发布失智症国家(地区)框架和标准策略 | √ | √ | - | - | √ | - | - | - | - | - | - | √ | - | - | - | √ | - | √ | √ | - | - | - | - | √ | √ | √ | |
失智症作为公共卫生优先事项 | - | - | - | √ | √ | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | √ | √ | - | - | √ | - | - | |
识别和描述早期认知障碍 | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | √ | - | - | - | - | - | - | - | - | - | - | - | |
基于社区的预防和管理 | - | - | - | - | - | - | - | - | - | - | √ | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | - | |
促进大脑健康 | - | - | - | - | - | √ | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | |
干预 | 失智症诊断、治疗、照护及干预 | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | - | - | √ | √ | √ | √ | √ | √ | - | √ | - | - |
减少不适当的抗精神病药物处方 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | √ | - | - | - | - | - | - | - | |
失智症患者的注册、分类管理 | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
对有失踪风险的患者做出快速响应 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | |
研究 | 建设失智症信息系统 | - | - | - | √ | - | - | √ | √ | √ | √ | - | - | - | √ | - | √ | √ | √ | √ | √ | - | - | - | √ | - | √ |
失智症研究、教育和创新 | - | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | |
患者在社会建筑环境中生活得更好 | √ | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | √ | - | √ | - | - | √ | - | - | √ | - | |
开发卫生和社会福利技术 | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
技术的可获得性 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | |
支持 | 对失智症照料者的支持 | - | √ | - | √ | √ | √ | √ | √ | √ | √ | - | √ | √ | - | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ | √ |
扩大不同护理服务主体的协调与合作 | - | - | - | - | - | - | - | - | √ | - | √ | - | - | √ | - | √ | - | - | √ | - | - | - | √ | √ | √ | √ | |
提高照护人员专业发展 | - | - | - | - | - | - | - | - | √ | - | - | √ | - | √ | √ | - | - | - | - | - | - | - | - | - | - | √ | |
确保患者和护理人员的参与性和自主性 | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | √ | - | - | √ | - | - | - | - | - | - | - | |
实施 | 建立战略领导管理小组 | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | - | - | √ |
保障行动计划实施所需资源 | - | √ | - | - | - | - | - | - | - | √ | - | √ | - | √ | - | - | - | - | √ | - | - | √ | √ | √ | |||
优化利益相关者的作用 | - | - | - | - | - | - | - | - | - | - | - | - | - | √ | - | - | - | - | √ | - | - | - | - | - | - | - | |
立法 | 护理人员的道德和赋权 | - | - | - | √ | - | - | - | - | √ | - | - | √ | - | - | - | - | √ | - | √ | - | - | - | - | - | - | - |
保护失智症患者的权益 | - | √ | - | √ | - | - | - | √ | - | - | - | - | - | √ | √ | - | - | - | √ | - | - | - | - | √ | √ | - | |
评估 | 持续护理、临终支持的质量 | - | √ | √ | - | - | - | - | - | - | √ | - | - | - | - | - | - | - | - | √ | - | √ | √ | √ | √ | - | √ |
服务的经济可持续性 | - | - | - | - | - | - | - | - | - | - | √ | - | √ | - | - | - | - | √ | - | - | - | - | √ | - | √ | - | |
结果完成情况、时间进度 | - | - | - | - | - | - | - | - | √ | √ | - | - | - | √ | - | - | - | - | - | - | - | - | - | √ | - | √ |
[1] |
中国痴呆与认知障碍诊治指南写作组,中国医师协会神经内科医师分会认知障碍疾病专业委员会.中国阿尔茨海默病一级预防指南[J].中华医学杂志,2020,100(35):2721-2735. DOI:10.3760/cma.j.cn112137-20200702-02017.
|
[2] |
|
[3] |
郑远长. 关于我国失智老年人研究工作综述及相关数据的比较分析[J]. 社会福利(理论版),2021,30(2):3-15.
|
[4] |
World Health Organization. Global status report on the public health response to dementia[R]. Geneva:World Health Organization,2021.
|
[5] |
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050:an analysis for the Global Burden of Disease Study 2019[J]. Lancet Public Health,2022,7(2):e105-125. DOI:10.1016/s2468-2667(21)00249-8.
|
[6] | |
[7] |
Alzheimer's Disease International. Dementia statistics[EB/OL]. [2022-02-01].
|
[8] |
World Health Organization. Global action plan on the public health response to dementia 2017—2025[R]. Geneva:World Health Organization,2017.
|
[9] |
Australian Government Department of Health. National framework for action on dementia 2015—2019[EB/OL]. [2022-02-03].
|
[10] |
Ministry of Health and Welfare. The Third National Dementia Plan in Korea:living well with dementia in the community[EB/OL]. [2022-02-05].
|
[11] |
Department of Health. Living well with dementia:a National Dementia Strategy[M]. London:Department of Health,2009.
|
[12] |
Finnish Ministry of Social Affairs and Health. National Memory Programme 2012—2020. Creating a "memory-friendly" Finland[EB/OL]. (2013-03-23)[2022-02-10].
|
[13] |
Danish Ministry of Health. A safe and dignified life with dementia:national action plan on dementia 2025[EB/OL]. [2022-02-15].
|
[14] |
Ministry of Health of the Czech Republic. National Action Plan for Alzheimer's disease and other similar diseases 2020—2030[EB/OL]. [2022-03-10].
|
[15] |
U.S. Department of Health and Human Services. National Plan to Address Alzheimer's disease:2019 update[EB/OL]. [2022-02-20].
|
[16] |
|
[17] |
Public Health Agency of Canada. A dementia strategy for Canada:together we aspire(2019)[EB/OL]. [2022-03-11].
|
[18] |
Ministry of Health Republic of Indonesia. National strategy management of Alzheimer and other dementia diseases:towards healthy and productive older persons[EB/OL]. [2022-03-11].
|
[19] |
Ministry of Public Health. Qatar national dementia strategy summary 2018—2022[EB/OL]. [2022-03-11].
|
[20] |
Federal Ministry Labour,Social Affairs. Austria—dementia strategy:living well with dementia[EB/OL]. [2022-03-11].
|
[21] |
Dementia Oversight of Implementation and Impact Group. Dementia action plan for Wales 2018—2022[EB/OL]. (2018-02-14)[2022-03-11].
|
[22] |
Greek Republic,Ministry of Foreign Affairs. National action plan for dementia:Alzheimer's disease 2015—2020[EB/OL]. [2022-03-15].
|
[23] |
State of Israel Ministry of Health. Addressing Alzheimer's and other types of dementia:Israel national strategy[EB/OL]. [2022-03-15].
|
[24] |
Sottish Government. Scotland's national dementia strategy 2017—2020[EB/OL]. (2017-06-28)[2022-03-15].
|
[25] |
Federal Office of Public Health,Conference of Swiss State Health Directors. Switzerland national dementia strategy 2014—2019[EB/OL]. [2022-03-15].
|
[26] |
Luxembourg's Health and Family Ministries. National dementia action plan[EB/OL]. [2022-03-15].
|
[27] |
Norwegian Ministry of Health and Care Services. Norway-dementia plan 2015—2020[EB/OL].[2022-03-15].
|
[28] |
The Alzheimer Society of Ireland. Ireland-national dementia strategy 2011—2016[EB/OL].[2022-03-15].
|
[29] |
Ministry of Health,Welfare and Sport. National dementia strategy 2021—2030[EB/OL].[2022-03-15].
|
[30] |
Parliamentary Secretariat for Rights of Persons with Disability and Active Ageing. Malta-empowering change 2015—2023[EB/OL].[2022-03-15].
|
[31] |
Ministry of Health. National dementia strategy 2014[EB/OL].[2022-03-15].
|
[32] |
Slovenia. National Plan 2016—2020[EB/OL].[2022-03-15].
|
[33] |
宁吉喆. 第七次全国人口普查主要数据情况[J]. 中国统计,2021,69(5):4-5.
|
[34] |
|
[35] |
|
[36] |
|
[37] |
国家卫生健康委办公厅关于探索开展抑郁症、老年痴呆防治特色服务工作的通知[A/OL]. [2022-04-05].
|
[38] |
|
[39] |
World Health Organization. Risk reduction of cognitive decline and dementia WHO guidelines,2019[EB/OL]. [2022-04-05].
|
[1] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[2] | XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109. |
[3] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[4] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[5] | WANG Jiaxin, ZHAO Yali. Domestic and International Assessment Tools for Medical Teamwork: a Systematic Review [J]. Chinese General Practice, 2023, 26(31): 3951-3962. |
[6] | WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733. |
[7] | YUAN Xiwei, NAN Yuemin. Research Progress of Structure, Function and Mechanism of Action of Mitofusin 2 in Liver Diseases [J]. Chinese General Practice, 2023, 26(30): 3841-3846. |
[8] | XIAO Yuqian, BAI Yanjie, WANG Yan, CHEN Shuying, CHEN Limin, SUN Kexin, WAN Jun. Research Progress of Mitochondrial Transfer in Post-stroke Cognitive Impairment [J]. Chinese General Practice, 2023, 26(30): 3833-3840. |
[9] | ZHOU Sijing, LUO Bangan, CAO Hui, ZHANG Xi, WANG Dongxin. Epidemiological Characteristics of Dementia and Its Correlation with Multimorbidity among Residents Aged 65 and Above [J]. Chinese General Practice, 2023, 26(29): 3616-3621. |
[10] | LIU Yu, YUE Ting, YANG Dongyu, ZHAO Zhongting, YANG Jibo, ZHU Tiantian. Research Progress on Mechanism of Autophagy in the Pathogenesis of Rheumatoid Arthritis [J]. Chinese General Practice, 2023, 26(29): 3710-3714. |
[11] | PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703. |
[12] | REN Yanfeng, LIU Shimeng, TAO Ying, CHEN Yingyao. A Systematic Review of Medication Preferences for Patients with Depression Based on Discrete Choice Experiment and Best-worst Scaling [J]. Chinese General Practice, 2023, 26(28): 3559-3564. |
[13] | LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341. |
[14] | CHEN Xiaofen, CHEN Yuhan, MA Juan. Recent Strides in Novel Treatments for Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(27): 3349-3354. |
[15] | LIU Yue, LIU Qi, DONG Hui, LIU Yaling. Neuropsychological Changes of Cognitive Reverters after Stroke Based on the Montreal Cognitive Assessment (MoCA) with a Double Threshold [J]. Chinese General Practice, 2023, 26(27): 3417-3422. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||